Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actazin vs PEG 3350 for Pediatric Constipation
NCT06836024Phase 3Not yet recruiting
- Sponsor
- Hamilton Health Sciences
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial (2 arms), sponsored by Hamilton Health Sciences. Primary endpoints: Consent Rate at 18 months, 4-week Follow up rates and 1 more. Planned start Jun 2025; status: not yet recruiting.
Beyond the preview
Go deeper on NCT06836024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06836024.